Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III maintenance study of bevacizumab + taxane versus bevacizumab + exemestane in estrogen receptor-positive advanced or metastatic breast cancer
2009-016338-29Phase 3Completed
- Sponsor
- ARCAGY
- Start
- Nov 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, exemestane, paclitaxel and docetaxel in breast cancer (2 arms), sponsored by ARCAGY. Primary endpoint: Progression-free survival. Started Nov 2009; status: completed.
02
Drugs
bevacizumabexemestanepaclitaxeldocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-016338-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016338-29.